UP!

ACAD $38.79   View long term graphs

Acadia Pharmaceuticals
Type
Public
Traded as NASDAQ: ACAD
Industry Biopharmaceutical, Healthcare
Founded 1993
Headquarters San Diego, CA, U.S.
Key people
Stephen R. Davis
CEO
Products Pimavanserin
Revenue Increase $42.13M (2011)
Operating income
Increase $22.85M (2011)
Net income
Increase $22.76M(2011)
Total assets Increase 108.71M (2012)
Number of employees
95
Website

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase IV development as a treatment for Parkinson's disease psychosis. It is also developing AGN XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. The product candidates in the company's pipeline emanate from discoveries made using its proprietary drug discovery platform.

Acadia Pharmaceuticals extended its drug discovery and development research agreement with Allergan to March 2012. The agreement stipulates both parties will work together for the discovery of new therapeutics for glaucoma and ophthalmic conditions.

News

ACADIA Pharmaceuticals Inc. 0.47% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-24 Future report Set alerts
Q3 2020 2020-10-28 Future report Set alerts
Q2 2020 2020-08-05 -0.27 -0.27
Q1 2020 2020-05-07 -0.57 -0.57
Q4 2019 2020-02-26 -0.34 -0.34
Q3 2019 2019-10-30 -0.29 -0.29
Q2 2019 2019-07-31 -0.38 -0.38
Q1 2019 2019-05-01 -0.59 -0.59
Q4 2018 2019-02-26 -0.50 -0.50
Q3 2018 2018-11-06 -0.50 -0.50

Ratings

2016-07-08 Reiterated Rating Piper Jaffray Cos. Overweight $44.00
2016-06-22 Downgrade Bank of America Buy to Neutral $40.00
2016-06-22 Downgrade Bank of America Corp. Buy to Neutral $40.00
2016-05-22 Reiterated Rating Leerink Swann Hold
2016-05-19 Reiterated Rating Piper Jaffray Positive $44.00
2016-05-19 Reiterated Rating Piper Jaffray Cos. Positive $44.00
2016-05-06 Reiterated Rating HC Wainwright Buy
2016-05-05 Reiterated Rating Piper Jaffray Overweight $44.00
2016-05-05 Reiterated Rating Cowen and Company Outperform $41.00
2016-05-03 Downgrade Leerink Partner Outperform to Market Perform
2016-05-03 Downgrade Leerink Swann Outperform to Market Perform $40.00 to $35.00
2016-04-17 Reiterated Rating Cowen and Company Buy
2016-04-01 Reiterated Rating Aegis Buy $54.00
2016-03-31 Reiterated Rating Needham & Company LLC Buy $49.00
2016-03-30 Boost Price Target Piper Jaffray Overweight $39.00 to $44.00
2016-03-28 Reiterated Rating JPMorgan Chase & Co. Buy
2016-03-28 Reiterated Rating Bank of America Buy
2016-03-28 Reiterated Rating Leerink Swann Outperform $40.00
2016-03-28 Reiterated Rating HC Wainwright Buy $50.00
2016-03-27 Reiterated Rating Piper Jaffray Buy $39.00 to $44.00
2016-03-22 Reiterated Rating JMP Securities Outperform $43.00
2016-03-15 Reiterated Rating Needham & Company LLC Buy $49.00
2016-03-02 Reiterated Rating Leerink Swann Buy $40.00
2016-02-24 Lower Price Target JPMorgan Chase & Co. Neutral $75.00 to $61.00
2016-02-08 Initiated Coverage Bank of America Buy $40.00
2016-01-26 Reiterated Rating Aegis Buy
2016-01-22 Upgrade Piper Jaffray Neutral to Overweight $39.00
2015-12-15 Reiterated Rating Leerink Swann Outperform $52.00 to $47.00
2015-11-07 Reiterated Rating Leerink Swann Buy
2015-11-06 Reiterated Rating Cowen and Company Buy $50.00
2015-11-06 Boost Price Target Leerink Swann Outperform $48.00 to $52.00
2015-11-06 Downgrade Piper Jaffray Overweight to Hold $48.00 to $39.00
2015-09-16 Initiated Coverage JPMorgan Chase & Co. Hold
2015-09-04 Reiterated Rating JPMorgan Chase & Co. Buy $55.00
2015-09-03 Reiterated Rating Needham & Company LLC Buy $49.00
2015-09-01 Initiated Coverage Leerink Swann Buy
2015-08-28 Reiterated Rating Cowen and Company Buy $50.00
2015-08-27 Upgrade Piper Jaffray Neutral to Overweight $48.00
2015-08-25 Initiated Coverage Aegis Buy $54.00
2015-08-07 Boost Price Target JPMorgan Chase & Co. Overweight $45.00 to $55.00
2015-08-07 Reiterated Rating Cowen and Company Outperform $43.00 to $50.00
2015-08-07 Boost Price Target Needham & Company LLC Buy $38.00 to $49.00
2015-08-07 Downgrade Piper Jaffray Overweight to Neutral $39.00 to $48.00
2015-07-02 Reiterated Rating HC Wainwright Buy $50.00
2015-05-08 Set Price Target Needham & Company LLC Buy $38.00
2015-05-08 Reiterated Rating JPMorgan Chase & Co. Buy $40.00 to $45.00
2015-04-16 Initiated Coverage Leerink Swann Outperform $48.00
2015-03-12 Reiterated Rating Piper Jaffray Overweight $39.00
2015-03-12 Lower Price Target Jefferies Group Buy $50.00 to $47.00
2015-03-12 Lower Price Target Needham & Company LLC Buy $40.00 to $38.00
2015-03-10 Reiterated Rating HC Wainwright Buy
2015-02-27 Reiterated Rating Needham & Company LLC Buy $40.00
2015-02-27 Boost Price Target JMP Securities Outperform $31.00 to $50.00
2015-02-24 Initiated Coverage HC Wainwright Buy $50.00
2015-02-06 Reiterated Rating Roth Capital Buy $42.00
2015-01-28 Boost Price Target Jefferies Group Buy $42.00 to $50.00
2014-12-22 Boost Price Target Needham & Company LLC Buy $26.00 to $40.00
2014-11-21 Initiated Coverage Cowen and Company Outperform $46.00
2014-05-15 Initiated Coverage Morgan Joseph Overweight
2014-05-15 Initiated Coverage JPMorgan Chase & Co. Overweight $33.00
2014-03-04 Boost Price Target Jefferies Group $26.00 to $38.00
2013-10-07 Initiated Coverage Ned Davis Research Neutral
2013-08-07 Reiterated Ladenburg Thalmann Buy $15 to $24
2013-08-07 Downgrade MLV & Co Buy to Hold $18 to $20
2013-04-11 Reiterated Needham Buy $9 to $16
2013-04-11 Reiterated MLV & Co Buy $12.50 to $18
2013-04-11 Reiterated Ladenburg Thalmann Buy $9 to $15
2013-03-13 Reiterated Ladenburg Thalmann Buy $8 to $9
2012-11-28 Reiterated MLV & Co Buy $4.50 to $8.50
2012-11-27 Reiterated Ladenburg Thalmann Buy $8
2012-04-30 Initiated Ladenburg Thalmann Buy
2009-09-01 Downgrade Citigroup Hold to Sell
2009-05-05 Upgrade JMP Securities Mkt Perform to Mkt Outperform $7
2008-07-08 Upgrade Banc of America Sec Sell to Neutral
2008-06-17 Downgrade Jefferies & Co Buy to Hold $14 to $4
2008-06-17 Downgrade Friedman Billings Outperform to Mkt Perform $21 to $8
2008-06-17 Downgrade Banc of America Sec Buy to Sell
2008-05-06 Reiterated Brean Murray Sell $7 to $6
2008-03-07 Reiterated Fortis Bank Buy $22 to $23
2016-07-08 Reiterated Rating Piper Jaffray Cos. Overweight $44.00
2016-06-22 Downgrade Bank of America Buy to Neutral $40.00
2016-06-22 Downgrade Bank of America Corp. Buy to Neutral $40.00
2016-05-22 Reiterated Rating Leerink Swann Hold
2016-05-19 Reiterated Rating Piper Jaffray Positive $44.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
14159, L.P. 20.39%  (20278008) ACAD /
BAKER BROS. ADVISORS LP 0.49%  (489977) ACAD / ALXN / AQXP / BCRX / GHDX / IDRA / INCY / MRTX / SGEN / XOMA /
BAKER FELIX 0.44%  (440802) ACAD / ALXN / BCRX / GEVA / GHDX / MRTX / SGEN /
GRAY MARY ANN 0.15%  (149476) ACAD / CBRX / DYAX / GALE / SNMX / TELK / TLOG /
Hacksell Uli CEO 0.12%  (115549) ACAD /
Baity Glenn VP AND GC 0.08%  (83734) ACAD /
Iversen Leslie L 0.04%  (36127) ACAD /
Mills Roger EXEC VP 0.02%  (18550) ACAD /
KAPLAN LESTER J PH D 0.02%  (17000) ACAD /
SOLAND DANIEL B 0.01%  (10000) ACAD / VPHM /
Moore Terrence O EVP, CHIEF COMMERCIAL OFFICER 0.01%  (9527) ACAD / TSPT /
Rasmussen Torsten 0.01%  (8500) ACAD /

Comments